BioLineRx announces $10M registered direct offering

BioLineRx (BLRX) announced that it has entered into definitive agreements for the purchase of an aggregate of 50M of the company’s American Depositary Shares and accompanying warrants to purchase up to an aggregate of 50M ADSs, at a purchase price of 20c per ADS and accompanying warrant in a registered direct offering. The warrants will have an exercise price of 20c per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date. Each ADS represents fifteen ordinary shares, par value NIS 10c per share, of BioLineRx. The closing of the offering is expected to occur on or about January 7, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.